- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Merck KGaA (EMD in North America) announced today an alliance with Nano Terra LLC, a leading nanotechnology co-development company, designed to bring to market innovative, nanotechnology-based products and solutions.
Under the agreement, Nano Terra will develop solutions with Merck to create new physical properties in specialty chemicals, currently manufactured and sold by Merck. These new properties are made possible through nano-scale, molecular fabrication methods pioneered by Nano Terra and its Co-Founder, Professor George M. Whitesides of Harvard University. The new solutions will allow Merck's proprietary materials to be used with significantly greater precision and control, and allow for new applications at reduced economic levels never before possible.
The development work will be done primarily at Nano Terra's lab facilities in Cambridge, with close cooperation of a Merck scientific team. Local support for the alliance will be provided by EMD Chemicals, Merck's North American affiliate.
The two companies anticipate that first new solutions will be presented to Merck customers by early 2008. The partners will share commercialization rights on a global basis. Financial terms of the agreement were not disclosed.
"Merck is a world leader in research-driven pharmaceutical and chemical products, and the goal of this alliance is to work with them to develop innovative nanotechnology solutions that dramatically expand the addressable markets for their materials," said Carmichael Roberts, Vice Chairman of Nano Terra. "We are very proud to have been selected by them because of our scientific capabilities."
Dr. Thomas Geelhaar, Vice President Liquid Crystals R&D and Business Development Chemicals of Merck KGaA, added: "We have long been fascinated by the sciences originally developed by Professor George Whitesides of Harvard and, through his association with Nano Terra, we look forward to being amongst the first to commercialize these innovations with them." In 2006, Merck bestowed on Professor Whitesides the prestigious Emanuel Merck Lectureship p
About Nano Terra LLC
Nano Terra is a privately held research and development company which custom develops nano technology solutions for Fortune 500 companies. Many of its sciences are based on the life work of Professor George Whitesides, the Woodford L. and Ann A Flowers University Professor at Harvard University, and are based on biochemistry, materials science, catalysis and physical organic chemistry.
About EMD Chemicals Inc.
EMD Chemicals represents the North American chemical sector of Merck KGaA, Darmstadt, Germany. As an international organization with 1,100 employees and revenues of more than $US 350 million, EMD Chemicals focuses on specialty chemicals for pharmaceutical, biotech, cosmetic, agricultural, automotive, plastics, electronics and other industrial applications.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.subscribe.merck.de to register online, change your selection or discontinue this service.
Merck is a global pharmaceutical and chemical company with sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future shaped about 35,000 employees (including Merck Serono) in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please click here
Nano Terra LLC
Barbara Lyon, 617-621-8500
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016
Thomas Swan and NGI announce unique partnership July 28th, 2016